These data demonstrated that the performance of individual Chinese laboratories for NGS-based ctDNA analysis continuously improved over time with participation in PT schemes. However, further care must also be taken in standardized operations and validations.
Clin Chem. 2022 Jun 10;hvac055.
Patients with ECRC might benefit from KRAS mutation testing but not from postoperative chemotherapy.
Front Oncol. 2022; 12: 897548.
We studied the role of EGFR and other driver mutations in their involvement in acquired resistance to treatment with EGFR-TKIs and we analyzed the role of liquid biopsy as a non-invasive diagnostic method. Our results showed that liquid biopsy is a very useful tool monitoring the evolution of the disease and the resistance to TKIs. The detection of other concomitant mutations in driver genes is also key in this regard, so we found that alterations in the NFI tumor suppressor gene could be playing a role in disease progression and resistance to targeted therapies.
Cancers (Basel). 2022 Jul 7;14(14):3323.
Selpercatinib, with potent and durable antitumor activity including intracranial activity, was well tolerated in Chinese patients with RET fusion-positive NSCLC, consistent with LIBRETTO-001 (ClinicalTrials.gov: NCT04280081).
Ther Adv Med Oncol. 2022 Jul 28;14:17588359221105020.
This retrospective study evaluated the clinical implications of CUL9 expression on the prognosis and the predictive value for postoperative adjuvant chemotherapy in consecutive patients with colon cancer.
Cancers. 2022 Aug 9;14(16):3843.
Combined models that incorporate radiomics signature, clinical,and CT morphological features may serve as an auxiliary tool to predict EGFRmutation subtypes and contribute to individualized treatment for patients with LADC.
Front Oncol. 2022 Aug 18;12:846589.